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Abstract
© 2017 Future Science Ltd. Clays for drug delivery have been used from ancient time due to the
large availability of clay minerals and their unprecedented properties. The empirical use of
nanoclays from the past is  converted in a stimulating scientific  task aimed at building up
nanoarchitectonic vehicles for drug delivery in a targeted and stimuli-responsive fashion. Here
the historical aspects are discussed; next the modern examples of applications of different clay-
based materials are discussed. A special focus is given to halloysite clay nanotubes, which are
an emerging and very promising nanomaterial for drug-delivery purposes due to its special
morphology  and  unique  chemical  properties.  Advantages  and  limitations  of  these  natural
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